Abstract. The aim of this study was the identification of surrogate markers of host immunity in renal cell carcinoma (RCC) patients. Using 4-color flow cytometry the immunophenotype of blood immune cells of RCC patients was compared to that of healthy volunteers and correlated with staging and grading of patients. Furthermore, the time course of these immune markers was compared in RCC patients undergoing either open surgery or laparoscopy. Compared to the healthy control group, blood of RCC patients contained more granulocytes and higher percentages of CTLA4 + cD8 + T lymphocytes, but reduced numbers of dendritic cells (DCs) and of CD28 + cD8 + T cells. Tumor progression was associated with a higher white blood cell count, a reduced frequency of blood DCs and increased numbers of CD57 + T and NK cells. Monocytes of patients with advanced RCC showed a reduced HLA-DR surface expression associated with higher aminopeptidase N(APN)/CD13 expression. Tumor surgery caused an increase of granulocytes and a decrease of all lymphocytic and DC subpopulations within 24 h, whereas the number of HLA-DR low monocytes was up-regulated. As demonstrated by time kinetic analysis, laparoscopic intervention caused a more moderate immunosuppression and an enhanced restoration of immune activity than open surgery. These results suggest that the composition and the phenotype of innate immune cells reflect well the differences in the cellular immunity of RCC patients associated with tumor disease as well as surgery. The monocytic HLA-DR intensity represents a suitable marker for monitoring tumor stage and surgery-associated immunosuppression in RCC patients.
Introduction
Renal cell carcinoma (RCC) is known as an immunosensitive tumor. Surgical management with radical or partial nephrectomy is the most effective treatment for patients with localized disease. In patients with advanced or recurrent metastatic RCC, immune modulation-based therapies, such as low dose Il-2 and IFn-α treatment have been used for more than 20 years to improve cancer-specific survival. However, the efficacy of both substances is rather low. Recently, targeted therapies have increased both objective response rates and disease-free survival of RCC patients, in particular drugs inhibiting the vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathway (1, 2) .
Accurate prediction of long-term disease-free survival immediately after surgical resection of clinically localized and advanced disease would be valuable for patient counseling, scheduling follow-up imaging and identifying poor risk group patients who might benefit from enrollment in adjuvant therapy protocols. However, so far tumor stage, tumor grade, and patient performance status remain the most useful and clinically available predictors of RCC patients' outcome (reviewed in ref. 3 ). Up to now, there exist only few data on prognosis-relevant markers of the immune system, among them a high number of blood granulocytes, which correlates with poor prognosis (4) . In addition, high number of regulatory T cells (Treg) and of myeloid suppressor cells (MDSC) in patients with advanced RCC could be associated with reduced survival (5-7).
Major surgical trauma promotes an immunologic dysfunction that predisposes patients to significant morbidity. Recent studies suggest that the impairment of the immune system parallels the degree of surgical trauma and tissue injury (8) . Deficient immune responses in the early postoperative period may facilitate the implantation of disseminated tumor cells and their early metastatic growth. Advances in laparoscopic approaches and equipment have allowed surgeons to perform technically more complex reconstructive and organ-preserving surgery. Since its introduction in 1990, the implementation of laparoscopic radical nephrectomy is increasing worldwide. In the hands of experienced laparoscopic urological surgeons
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and with adherence to established principles of open radical nephrectomy, laparoscopic radical nephrectomy is now the recommended standard of care for patients with T2 tumors and smaller renal masses not treatable by nephron-sparing surgery (9) . Advantages of laparoscopic techniques are less blood loss, faster recovery time and shorter hospital stay (10) . Minimally invasive methods are less stressful and appear to reduce the systemic acute phase reaction associated with open surgery. In our study the perioperative cellular immune responses were investigated in patients undergoing open and laparoscopic tumor surgery for localized RCC. Using multicolor flow cytometry, we first compared the composition of blood immune cells of RCC patients prior surgery with an agematched control group, correlated the phenotype of patients' immune cells with tumor stages and grades, and performed an one-week time kinetics of the blood immune cell repertoire in both patients groups. besides the quantification of blood immune cells, we chose markers of cellular activation (such as HLA-DR, CD25, CXCR3 for T cells), cellular senescence and exhaustion (e.g. CD57,CTLA4, PD1), and suppressive function (FoxP3). Furthermore, we quantified the expression of HLA-DR and aminopeptidase N/CD13 on monocytes, molecules known to be involved in antigen presentation.
Materials and methods
Patient samples. The study comprised 44 RCC patients who underwent surgery of the primary tumor at the Department of Urology of the Martin Luther University Halle-Wittenberg. Twenty-seven patients were operated per laparatomy and 17 patients with laparoscopy. The study was performed with the approval from the Ethics Committee of the University, and all patients gave their informed consent. The average age was 66.05 years (range 43-86 years). Twenty-four patients were male and 20 were female. Histology, tumor grading and staging are given in Table I . EDTA blood (9 ml) was received from RCC patients at least one day before operation as well as on days 1, 3 and 7 after surgery, and prepared within 4-6 h. Twenty healthy individuals with a mean age of 59 years (range 40-78 years) without tumor disease in clinical history served as controls.
Antibodies and sample preparation. A lysed whole blood technique with 4-color staining of blood cells was used. The monoclonal antibodies (mAbs) purchased from bD biosciences (Heidelberg, Germany) were CD3, CD8, CD19, CD25, CD56, CTLA4/CD152, PD1/CD279; those purchased from beckman Coulter GmbH (Krefeld, Germany) included CD14, CD16, CD28, CD57 and TCRVα24. The FoxP3 staining buffer set (clone PCH101) of ebioscience (San Diego, CA) was used for staining of CD4 + regulatory T cells. Circulating dendritic cell (DC) populations were identified by using a 'blood Dendritic Cell Enumeration Kit' according to the manufacturer's instructions (Miltenyi, bergisch Gladbach, Germany). briefly, aliquots of whole blood were labeled with a cocktail of mAbs including anti-CD14-PE-Cy5 and anti-CD19-PE-Cy5 plus or minus anti-CD1c-PE as a marker for type-1 myeloid DC (mDC1), CD141/bDCA-3-APC (mDC2) or CD303/bDCA-2-FITC for plasmacytoid DC (pDC). After incubation, red cell lysis and washing, cells were fixed and examined using a FACSCalibur and the Cellquest software (bD biosciences). Results are expressed as percentage of DC in white blood cells (WbC) or as absolute numbers/µl of blood.
The expression of HLA-DR and aminopeptidase N(APN)/ CD13 on monocytes was evaluated using mAbs labeled on a protein/fluorophore ratio of 1/1 (QuantibRITE™ reagents; bD biosciences). A standard curve for antigen quantification was established using multilevel calibrated QuantibRITE beads. The fluorescence was measured as specific geometric mean fluorescence intensity (MFI) of the gated population and converted into antibody molecules bound per cell (AbC) using Microsoft Excel™ spreadsheet. Taking the geometric mean representing 5,000 AbC as borderline value, we estimated the amount of HLA-DRlow monocytes as percentage of cD14 + cells. The anti-HLA-DR 1/1 PE (clone L243)/ anti-CD14 PerCP-Cy5.5 mAb (bD biosciences) was used according to the manufacturer's instruction and measured in 1 ml PbS without any washing steps. The CD13 antigen was detected using the mAb clone Leu-M7, prepared as a customer conjugate (bD biosciences). Staining for CD13 was done similarly as with HLA-DR, with the exception of two washing steps after lysis of erythrocytes. For the gating of monocytes, a CD14-specific FITC-labeled mAb was additionally included. Flow cytometric analysis of immune cells was performed using a FACSCalibur™ (bD biosciences) with the CellQuest™ software. Lymphocytes, monocytes and granulocytes were separated on the basis of their forward scatter and side scatter patterns, and the staining for CD14 was used to identify monocytes. At least 5,000 cells in the region of interest were counted.
Statistical analysis.
Results are given as the mean ± SEM. The statistical analysis was done using the commercial software SPSS 17.0 (SPSS Inc., Munich, Germany). Differences in the absolute cell count of immune cells and the relative percentages between patients and healthy volunteers, patients with different tumor stages and grading, and differences at each time point were analysed using Student's t-test, Wilcoxon-Mann-Whitney test, Kruskal-Wallis test and χ 2 test, respectively. All p-values are exploratory.
Results

Comparison of immune cells in RCC patients compared to a healthy control group.
In order to determine whether there exists a difference in the frequency and the phenotype of immune cell subpopulations between RCC patients and the age-matched control group, immunostaining of blood cells was performed with a large panel of mAbs. Despite the number of leukocytes was comparable between healthy donors and RCC patients, RCC patients exhibited a higher percentage of granulocytes and a lower percentage of lymphocytes as illustrated in Fig. 1A . The frequency of blood DC of RCC patients when compared to that of the control group was lower. Especially the mDC1 subpopulation of DC was depressed in patients, whereas no obvious difference could be found for mDC2 (data not shown) as well as pDC (Fig. 1b) . Using mAb with a protein/fluorophore ratio of 1/1, the monocytic expression of HLA-DR and APN/CD13 was quantified. Compared to healthy volunteers, monocytic HLA-DR expression was lower in RCC patients (p=0.089). Using a threshold of 5,000 AbC for a strongly diminished HLA-DR intensity on monocytes (HLA-DR low ), the control group possessed 2.8±0.6% and RCC patients 7.5±1.2% of these HLA-DR low monocytes (p=0.001), respectively.
In contrast, only minor differences could be found in the lymphocytic subpopulations of both groups. All the function-associated surface molecules investigated showed no significant differences with the exception of the numbers of CD28 + cD8 + T cells, which were lower in RCC patients than in the control group (Fig. 1C) , whereas CTLA4 + cD8 + T cells were higher in RCC patients (Fig. 1D) . In addition, a higher number of CD57 + T cells and CD57
+ NK cells could be detected in RCC patients (Table II) . No difference could be found for the number of FoxP3 + cD4 + regulatory T cells in the blood of control group and tumor patients (Table II) .
Tumor stage-dependent alterations of the immunophenotype. In order to determine whether there exists a tumor stage-dependent alteration in the frequency or phenotype of immune cell populations in peripheral blood, we compared the preoperative values of RCC patients with locally advanced (≥pT3) and early stage tumors (<pT3) ( Table II) . The ≥pT3 group had higher WbC due to an increased number of granulocytes ( Fig. 2A) . The number of monocytes was also higher in the patient group ≥pT3, whereas DC counts were lower (Fig. 2b) . Whereas patients with early tumor stages possessed 10.9 mDC1 cells/µl and 5.11 pDC cells/µl, we estimated 7.84 mDC1 cells/µl and 4.51 pDC cells/µl in patients with ≥pT3. WbC correlated with tumor stages (p=0.031), but not with tumor grades (data not shown). In addition, the absolute numbers of DC correlated both with tumor grading of RCC lesions and with tumor staging (data not shown), whereas the frequency of DC (as percentage of leukocytes) correlated only with tumor staging (p=0.009).
The intensity of monocytic HLA-DR expression was diminished in the patient group ≥pT3 (Fig. 2C) . This points to a decreased monocytic HLA-DR expression in advanced malignancy when compared to early tumor stages. Using the 5,000 AbC threshold, we observed 5.4±1.1% of HLA-DR low monocytes in patients with <pT3 and 12.6±2.4% of HLA-DR low monocytes in patients with ≥pT3. Furthermore, monocytic CD13 expression correlated with tumor staging exhibiting a higher intensity in advanced disease (Fig. 2C) .
The number of Vα24 + NKT cells was only marginally higher in RCC patients with advanced tumor stages. In addition, the absolute counts for T cells (CD3 + ), b cells (CD19 + ) and NK cells (CD3 -, cD56 + ) did not differ significantly between patients with early and advanced tumor stages (Table II) . However, despite a high variability between individual patients there was a tendency to a higher amount of cD4 + T cells in advanced RCC, whereas the number of cD8 + T cells remained similar in both groups. We found no significant difference in the absolute numbers of CD25 + cD4 (Fig. 2D) .
Post-operative changes in immune cells between laparotomy and laparoscopy.
Patients undergoing open tumor surgery spent on average 12.3±0.6 days in hospital care, patients with laparoscopic tumor surgery 10±0.6 days (p=0.016). This difference is caused by a higher percentage of advanced diseases in the laparotomy group, since patients with tumor stages pT1-2 were hospitalized a comparable time independent of the mode of surgery (data not shown). In order to investigate the immune competence and recovery of both patient groups, a set of immune cell parameters was measured before (p), one (d1), three (d3) and seven days (d7) after surgery. No significant differences between the pre-operative values within both groups of tumor surgery were found with the exception of the number of CD57 + T cells, which was higher in the open surgery group (p=0.047). One day after surgery (d1) the most obvious changes within the time course could be found. During the post-operative follow-up, all markers investigated did at least partially recover, often with a faster normalization in the laparoscopic group of patients. Most patients showed post-operatively elevated WbC counts caused in particular by a short-time increase of granulocytes (Fig. 3A) , whereas the number of lymphocytes dropped (Fig. 3C) . At time point d1, granulocytes rose to 142% of the preoperative value in case of the open surgery group and to 113% in the laparoscopy group. The absolute values of monocytes showed a slight increase at time point d1, with a further rise only in the laparoscopy group (significant difference at d3, Fig. 3b ). Otherwise lymphocytes decreased to 62% of the preoperative value in case of the open surgery group and to 70% in the laparoscopy group. At time point d1, the number of T-, b-and NK cells declined to 50-80% of the preoperative value (Table III) . Furthermore, most of the T cells with special function-associated surface molecules studied showed a decline at the first postoperative day (Table III) . In addition, blood DC declined after surgery and did not recover until 7 days in the laparotomy group with a significant difference at day 7.
Time kinetics revealed an immune depression of all RCC patients post-surgery documented by a decreased monocytic HLA-DR intensity (Fig. 4A) . At the first day after surgery, the percentage of HLA-DR low monocytes increased from 7 up to 30% of monocytes in the open surgery group and to 19% of monocytes in the laparoscopy patients (Fig. 4b) . The expression of monocytic HLA-DR expression slowly recovered over time, reaching pre-operative values only in the laparoscopic group within 7 days. Monocytic APN/CD13 The frequency of different immune cell subpopulations and respective functional immune parameters were determined by flow cytometry before operation (d0), at the first (d1), third (d3) and day 7 (d7) after surgery. Data are given as cells/µl (d0) and as relative values (percentage of d0).
expression increased on monocytes in both patient groups with a maximum at day 3 after surgery ( Fig. 4C) .
Discussion
Using multi-color flow cytometry, we searched for surrogate markers to monitor the immune cell repertoire and function in RCC patients before and after tumor surgery. An RCC-induced immune dysfunction in patients at first diagnosis has been described by Porta and co-authors (11) demonstrating a marked suppression of both CD4/CD45RA naive and CD4/CD45RO memory T cells, CD16 + NK cells, and total circulating DC despite a significant activation of HLA-DR + T lymphocytes and of the CD56 + NK cell subset. In addition, distinct peri-operative immunodysfunctions have been demonstrated in RCC patients, such as increased leukocyte and granulocyte counts, but low T cell counts until post-operative day 3 (12) . These results were extended by our study investigating differences: i) in immune cells between RCC patients and age-matched healthy volunteers; ii) between preoperative values of patients with early (<pT3) and locally advanced tumor stages (≥pT3); and iii) in the post-operative time course between laparoscopic and open surgery. We extended immune parameters on subpopulations of blood DC, several function-related markers of T cells and on the quantification of monocytic intensity of HLA-DR and APN/ CD13. Differences in cell numbers and functional surface marker expression were mainly observed in cells of the innate immune system, such as granulocytes, monocytes and DC, but rarely in T cells. For the first time, we here characterised immune cell markers associated with advanced tumor stages in RCC patients. Tumor staging represents the most useful and clinically available predictor of RCC patients' outcome. Comparing early stage RCC (<pT3) to the locally advanced disease (≥pT3), a higher WbC was detected in advanced tumor stages due to higher numbers of granulocytes. This is in line with multivariate analysis identifying a high blood neutrophil count (>6.0 x 10E9/l) as independent poor prognostic factor in patients with metastatic RCC receiving IL-2 (4). Furthermore, granulocytes might represent an adverse prognostic factor in patients with metastatic RCC treated with anti-VEGF agents (13) . The role of granulocytes in advanced tumor disease has not yet been elucidated in detail. However, tumors are known to both drive myelopoiesis, sometimes leading to a clinically apparent leukocytosis, and to inhibit the differentiation of myeloid cells, resulting in a qualitative change in myelopoiesis (reviewed in ref. 14) . Recent data revealed arginase-producing MDSC in RCC as a granulocytic subpopulation (15, 16) . Abrogation of the MDCS-mediated immune suppression results in the restoration of cytokine production and proliferation of T cells (15) . In addition, granulocytes can be present as tumor-associated immune cells with an ambiguous role. Tumor-infiltrating neutrophils deliver a potent proangiogenic moiety, i.e., the unencumbered inhibitor-free metalloprotease (MMP)-9 (17).
Our results demonstrate the suitability of blood DC number as marker of immune suppression, exhibiting lower counts in RCC patients compared to a healthy control group. The implementation of a commercially available test kit for whole blood analysis without any separation step for the cell labeling resulted in a lower blood DC count (0.24% of leukocytes) when compared to other authors using density gradient separation of mononuclear cells (≥0.6% of leukocytes) (18) . The blood DC were in particular low in patients with advanced tumor disease (≥pT3): DC correlated both with tumor staging and grading. Human blood contains different subgroups of DC precursors, among them conventional CD11c + mDC and pDC as the major producers of type I interferon (19) . Although CD141 + mDC2 have been demonstrated as the main human DC subset involved in stimulating CTL responses (20) , differences of blood DC observed in this study concerned the number of total DC as well as CD1c + mDC1, but rarely the mDC2 subset, which was lower than one tenth of the number of mDC1. It is noteworthy that the mDC1 frequency could predict progression-free survival in advanced RCC patients treated with sunitinib (18) .
Patients with temporary immunodeficiency are characterized by a diminished expression of the major histocompatibility complex (MHC) class II antigens on monocytes, which play a critical role in the induction of the cellular immune response (21) . Attenuation of HLA-DR on the surface of circulating monocytes is generally accepted as a reliable marker for an immune dysfunction and has been described in several patients, e.g. after multiple trauma, burn injury, or major surgery. The mechanisms involved in the regulation of HLA-DR include internalization of the HLA-DR β-chain after ubiquination via members of the MARCH ubiquitin ligase family (22) . Interestingly, MDSC can be defined as cells positive for CD14 with low or negative HLA-DR expression, and 0.9% of leukocytes of RCC patients exhibit such a phenotype (18) . For the first time, we measure the number of HLA-DR low monocytes in RCC patients on an antibodies-bound-per-cell level, which allowed to accurately quantify the absolute antigen expression level, taking variations in instrument performance into account. Fluorescence intensity calibration allows the establishment of a comparable window of analysis across different times and laboratories. Mean values of an HLA-DR expression <5,000 AbC for the whole monocytic population have been designated as 'immunoparalysis' in former studies (21) , since the patients are at high risk of infectious diseases. Despite the threshold of 5,000 AbC HLA-DR, used by us for identifying HLA-DR low monocytes, is an artificial one, we could show a difference between healthy controls and tumor patients as well as between patients with early and late RCC stages. This threshold value might be used for the investigation of patients with other tumor entities or for the monitoring of tumor therapies. The most obvious increase in the number of HLA-DR low monocytes was found at the first day after tumor surgery and was significantly higher in patients with open tumor surgery.
In an earlier study of polytrauma patients the observed decrease in monocytic HLA-DR expression was accompanied by a delayed strong increase of membrane peptidase APN/ CD13 expression (23) . In the present study, we describe for the first time that the decrease in monocytic HLA-DR intensity is paralleled by an increase in APN/CD13 intensity in advanced RCC tumor stages. Analogous to polytrauma patients after surgery, the decrease of monocytic HLA-DR expression after RCC surgery was accompanied by a time-delayed increase of APN/CD13 intensity. However, the molecular mechanisms resulting in the higher monocytic APN/CD13 expression after surgery or in advanced tumor stages remain to be elucidated. In addition to monocytic differentiation, lipopolysaccharide as ligand of a pattern recognition receptor (23) as well as the cytokines IL-4 (24) and TGF-β (25) can up-regulate monocytic APN/CD13 expression in vitro. Since elevated TGF-β concentrations have been detected in the sera of RCC patients (26) and since TGF-β is able to suppress HLA-DR expression (27) , this immunosuppressive cytokine might be involved in the observed effect. The functional consequences of a higher monocytic APN/CD13 intensity in patients with RCC stages of ≥pT3 remain elusive as well. The ubiquitously expressed ectopeptidase is involved in multiple cellular functions and has been proposed to play a role in the modulation of kinins, neuropeptides and chemotactic mediators as well as in adhesion, cell-cell interactions and signal transduction (reviewed in ref. 28) .
In this study, the frequency of lymphocytes was significantly lower in RCC patients, which was paralleled by a higher percentage of granulocytes. Though the preoperative absolute counts of T cells (both CD4 + and cD8 + cells) and b cells were often lower in RCC patients compared to healthy age-matched controls, this difference was not significant. A decreased function of circulating T cells has been described in many human malignancies (29) . In vitro data indicate that the same functional impairments seen in tumor infiltrating lymphocytes are found in both circulating and lymph node lymphocytes of patients with cancer. Thus, human tumors exert profound suppressive effects on both local and systemic antitumor immunity (30) . Functionally distinct T cell populations can be defined by the expression of specific cell surface antigens, e.g. the chemokine receptors CXCR3 and CCR5 have been discussed to be exclusively expressed on Th1 lymphocytes (31) . In this study, a higher number of CXCR3 + T cells was found in advanced RCC stages. In addition, the surface receptor CD57 expressed on both T and NK cells has been associated with a history of numerous cell divisions, short telomeres and replicative senescence (32) . A high frequency of CD57 + cytotoxic T cells in the blood of RCC patients has been found in earlier studies and has been discussed to represent a predictive marker for the survival of RCC patients (33) . Concerning CD57 expression of T and NK cells a tendency to a higher number of CD57 + cells in RCC patients compared to the control group as well as an increased CD57 expression in patients with advanced tumor stages compared to early stages was found: 51% of NK cells expressed CD57 in the age-matched control group, 62% of NK cells at the early and 70% at the late RCC stages. The high standard error of the mean for the number of the CD57 + T cells in patients with advanced tumor stages implies that there might exist different patient subgroups, which vary with respect to their outcome. A higher number of patients would be needed to clarify this point.
The molecular basis for the cell-intrinsic control of T cell activation and tolerance resides within groups of activating and inhibitory receptors. The molecules CTLA4/CD152 as well as PD1/CD279 represent negative regulators of T cells involved in peripheral tolerance and a higher number of T cells positive for these molecules was found by us especially in the advanced tumor stages. CTLA4 signaling via the costimulatory molecules CD80 and CD86 on antigen-presenting cells provides a negative feedback loop to activated T cells thereby dampening their activity (34) . Similarly, PD1 signals inhibit T-cell activation and proliferation and PD1 expression parallels T cell exhaustion in chronic viral infection (35) . Increased numbers of tumor-infiltrating immune cells expressing PD-1 were found in patients with high-risk RCC tumors (36) . In contrast, the inducible costimulator (ICOS) representing a stimulatory receptor on T cells (37) exhibits the smallest values in patients with advanced tumor stages. The circulating CD8 + cD28 -effector subpopulation might have a significant greater propensity to undergo spontaneous apoptosis in patients with cancer (30) . Indeed, higher amounts of cD8 + cD28 -T cells were found in RCC patients compared to the control, whereas the difference between early and late tumor stages was less pronounced. We observed no difference in the amounts of FoxP3 + regulatory T cells between tumor patients and the control group. This is in contrast to results of Griffiths et al (38) who reported a significant difference between renal cancer patients (2.5% FoxP3 + T cells) and the control group (1.5%). We estimated values of 4-6% FoxP3 + T cells associated with a high standard error. We are sure that the permeabilization process has a significant effect on our values and would prefer surface staining (such as CD127dimCD25 ++ cD4 + ) in future studies. Taken together, our study describes for the first time putative biomarkers, which might serve as useful tools for monitoring of immune cell functions in RCC patients pre-and post-surgery. Combining immunophenotyping with functional tests would be useful for a better estimation of the immune competence of patients. Furthermore, larger randomised trials determining the immune phenotype and the correlation of these markers with clinical data, in particular with the survival rate, will be required.
